Survival analyses of GSE10846 dataset revealed increased NAT10 expression was associated with shorter overall survival (OS) in DLBCL patients (p = .0026, Figure 1F), suggesting the potential prognostic value of NAT10 in DLBCL. The gene discussed is NAT10; the disease is diffuse large B-cell lymphoma.